Oral & Macrocyclic Peptides – Part 2
Advancing the Frontier of Peptide Therapeutics
4/21/2027 - April 22, 2027 ALL TIMES PDT
Cambridge Healthtech Institute's Oral & Macrocyclic Peptides conferences (parts 1 & 2) are among the few peptide therapeutics conferences devoted to chemistry. The cornerstone of this two-part meeting is oral and/or macrocyclic peptide design and discovery, reflecting the next generation of peptide therapeutics and this conference's claim to fame as the industry's first macrocyclic-focused conference. However, peptide chemistry with broad peptide drug discovery and development implications, such as those spurred by the flurry of GLP1-related peptide activity, and downstream peptide development, will also be considered because the industry's frontier of peptide chemistry is relatively new and the scientists as well as the molecules are advancing together. Join us for this recently expanded two-part program to share progress, challenges, and solutions among leading medicinal and drug development peptide chemists, who are often one and the same (unlike the case for small molecules).
Preliminary Agenda

PEPTIDES AS FACILITATORS

Peptide Drug Conjugates

Photo of Jefferson D. Revell, PhD, Principal Scientist, R&D & Discovery Sciences, AstraZeneca , Principal Scientist , R&D & Discovery Sciences , AstraZeneca
Jefferson D. Revell, PhD, Principal Scientist, R&D & Discovery Sciences, AstraZeneca , Principal Scientist , R&D & Discovery Sciences , AstraZeneca

PEPTIDE CHEMISTRY LATERAL LESSONS

Triple Agonism at FGF21, GLP1, and GIP Receptors to Combat Obesity: Chemistry, Scalability, and CMC Implications

Photo of Florence Brunel, PhD, Senior Principal Scientist, Novo Nordisk Inc. , Senior Principal Scientist , Novo Nordisk
Florence Brunel, PhD, Senior Principal Scientist, Novo Nordisk Inc. , Senior Principal Scientist , Novo Nordisk

Manufacturing Challenges of Tirzepatide

Stephanie R. Coffin, PhD, Senior Director, Eli Lilly and Company , Sr Dir , Eli Lilly & Co

Small Molecule Versions of Obesity-GPCR Peptide Agonists 

Photo of Ching-Hsuan Tsai, PhD, Executive Director, Structure Therapeutics , Executive Director , Platform , Strucutre Therapeutics
Ching-Hsuan Tsai, PhD, Executive Director, Structure Therapeutics , Executive Director , Platform , Strucutre Therapeutics

New Perspectives on Chugai's Peptide Library and Hit-Discovery Technologies

Photo of Atsushi Ohta, PhD, Head of Modality Technology, Chugai Pharmaceutical Co., Ltd. , Head , Modality Technology , Chugai Pharmaceutical Co. Ltd.,
Atsushi Ohta, PhD, Head of Modality Technology, Chugai Pharmaceutical Co., Ltd. , Head , Modality Technology , Chugai Pharmaceutical Co. Ltd.,

PLENARY SESSIONS

PLENARY KEYNOTE

Photo of Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc
Gwenn Hansen, PhD, CSO, Nurix Therapeutics, Inc. , Chief Scientific Officer , Research , Nurix Therapeutics Inc

PLENARY PANEL: INSIGHTS FROM VENTURE CAPITALISTS

Panel Moderator:

PANEL DISCUSSION:
VC Insights on Drug Discovery Trends

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

Panelists:

James Edwards, PhD, Venture Partner, Samsara BioCapital , Venture Partner , Samsara BioCapital

Jamie Kasuboski, PhD, Partner, Luma Group , Partner , Luma Group

KT Moortgat, PhD, Managing Partner & Founder, Dalena Capital , Managing Partner & Founder , Dalena Capital

Sonia Setayesh, PhD, Partner, Civilization Ventures , Partner , Civilization Ventures

Daniella Tedesco, Partner & Co-Founder, NextRound Philanthrophy , Co-Founder , NextRound Philanthrophy


For more details on the conference, please contact:
Anjani Shah, PhD
Senior Conference Director
Cambridge Healthtech Institute
(+1) 781-247-6252
Email: ashah@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com


Register Early for Maximum Savings

APRIL 19

Covalent & Induced Proximity-Based Therapies

RNA-Modulating Small Molecule Drugs

Generative AI for Drug Discovery

training seminars

View In-Person Short Courses

APRIL 20 - 21

Degraders & Molecular Glues - Part 1

Small Molecule Discovery Technologies

AI/ML for Early Drug Discovery - Part 1

Linker & Conjugation Chemistries

Peptides

APRIL 21 - 22

Degraders & Molecular Glues - Part 2

Protein-Protein Interactions / Difficult Targets

AI/ML for Early Drug Discovery - Part 2

DNA-Encoded Libraries

GLP1 & Oral Peptides


Drug Discovery Chemsitry Europe

View All Sponsors

View All Media Partners